News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Illumina, Inc. (ILMN) Comments on a Ruling in its Patent Litigation Against Complete Genomics, Inc.


10/19/2012 9:05:18 AM

SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ: ILMN) announced today that Magistrate Judge Elizabeth D. LaPorte of the U.S. District Court for the Northern District of California granted a motion for summary judgment of invalidity filed by Complete Genomics, Inc. against certain claims of Illumina’s U.S. Patent No. 6,306,597. Over Illumina’s objections, the Court found that these claims were not novel over the prior art. The summary judgment ruling did not address a number of additional patent claims being asserted by Illumina against Complete Genomics that were not the subject of the validity motion.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES